Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

L’Oréal just announced it acquired a 10% stake in Galderma, characterized as a “pure play dermatology leader” in injectibles with Botox-competitor Dysport, and Restylane filler brands.

New pooled data from three Galderma studies of the Restylane portfolio will be presented, demonstrating that treatments with Restylane RefyneTM and Restylane DefyneTM not only enhance ...

(BUSINESS WIRE )--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® LyftTM or ContourTM in combination with Sculptra® in patients ...

Galderma Group AG operates as a dermatology ... Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, January 14, 2025--Galderma ...

Galderma Group AG operates as a dermatology ... Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, December 13, 2024--Galderma ...